Zhejiang Huahai Pharmaceutical’s 1H26 preliminary results beat expectations, but Goldman Sachs maintains Sell

Overview

This report is Goldman Sachs’ review of Zhejiang Huahai Pharmaceutical’s 1H26 guidance update. The company released its 1H26 guidance on July 5, 2026, with net profit far above Goldman Sachs’ prior expectation. On this basis, Goldman Sachs raised its 2026E to 2028E earnings forecasts and increased the 12-month target price from Rmb12 to Rmb13, while keeping a Sell rating.

Core views

The core view is that the short-term beat in earnings improves profitability visibility, but is not enough to change the negative investment stance. Zhejiang Huahai Pharmaceutical has driven generic-drug export growth through global channel expansion and new product launches, but persistent U.S. generic market pressure, higher R&D spending, patent litigation costs, and valuation above the 5-year forward average P/E keep the risk-reward unattractive.

Analysis framework

The report starts from the gap between the guidance and Goldman Sachs’ prior forecasts, decomposes the sources of the net profit beat, and simultaneously updates 2026E to 2028E revenue, EBITDA, and EPS forecasts. Valuation continues to use the 19x 5-year exit P/E methodology, combining 5-year EPS CAGR and A/H premium to derive the 12-month target price.

Methodology notes

• Valuation methods5-Year Exit P/E Valuation Method

  19x 5-yr exit P/E

  Goldman Sachs maintains the 19x 5-year exit P/E method and applies a 6% 5-year EPS CAGR and a 37.5% A/H premium, resulting in a 12-month target price of Rmb13.

• Factor FrameworkGS Factor Profile

  Growth, Financial Returns, Multiple, Integrated

  Goldman Sachs’ factor framework compares the stock with the market and industry peers across growth, financial returns, valuation multiples, and integrated factors to provide investment context.

• M&A FrameworkM&A Rank

  M&A Rank 3

  The report indicates Zhejiang Huahai Pharmaceutical has an M&A Rank of 3, meaning the likelihood of being acquired is low and it is generally not included in target price derivation.

• Data ToolsQuantum

  Goldman Sachs proprietary database

  Quantum is Goldman Sachs’ proprietary database for financial history, forecasts, and ratio analysis, supporting in-depth single-stock analysis and cross-company comparison.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Zhejiang Huahai Pharmaceutical (600521.SS)

  Research target; China A-share pharmaceutical company

  Strengths

  Transformed from an API company into a leading domestic generic-drug exporter focusing on the U.S. and China; 1H26 guidance is above expectations; global sales-channel expansion and new product launches support growth.

  Weaknesses

  Significant profitability pressure remains in the U.S. generic market, while R&D costs and patent litigation costs are increasing; current valuation is above the 5-year forward average P/E.

  Comparison

  Goldman Sachs’ rating is positioned relative to its China A-share healthcare coverage universe; the report argues valuation is currently high and risk-reward is weaker than more attractive peers in the same coverage set.

  Risks

  If pipeline product deliveries and sales ramp are stronger than expected, if API prices rise, or if U.S. sales recover materially faster, the Sell rating faces upward revision risk.

Key data

• 1H26 Forecast Net ProfitRmb757mn-Rmb799mnUp 85%-95% year-on-year, above Goldman Sachs’ previous forecast of Rmb540mn.
• Sandoz CompensationUSD7mnThe company expects this compensation to add Rmb82mn to net profit.
• 12-Month Target PriceRmb13The prior target price was Rmb12; this is raised but still below the Rmb15.41 closing price.
• Implied Downside15.6%Based on a Rmb13 target price and the July 3, 2026 close of Rmb15.41.
• 2026E Revenue ForecastRmb8,721.7mnPrevious forecast was Rmb8,627.1mn.
• 2026E EPS ForecastRmb0.58Previous forecast was Rmb0.54.
• 2026E P/E26.4xCalculated in the table based on Goldman Sachs forecasts and FactSet pricing.
• Market CapitalizationRmb23.1bn / USD3.4bnDisclosed in the report tables.

Impact & implications

The guidance update improves near-term earnings recovery visibility and supports a target price increase, but because the target remains below the current market price, the report’s conclusion on the stock remains negative. For investors, the key question is whether the expansion of sales channels and scaling of new products can sustainably offset U.S. generic price pressure, rising costs, and litigation expenses.

Risks

• If pipeline product delivery and sales ramp are better than expected, earnings and valuation may be upgraded.
• Rising API prices could improve margins and create upside risk.
• If U.S. market sales recover more strongly than expected, Goldman Sachs’ negative view may weaken.
• U.S. generic market competition, R&D spending, and patent litigation costs may continue to pressure profitability.
• A valuation level above the 5-year forward average P/E makes the stock more sensitive to disappointing earnings.

What to watch

• Outcomes of U.S. FDA inspections for relevant companies.
• Progress of new product launches in the U.S. and European markets.
• Whether global sales-channel expansion can continue to deliver revenue year-on-year growth.
• The quality of recurring profit recovery beyond Sandoz compensation.
• Whether 2026E to 2028E EPS forecasts can be delivered.